Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 913

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 913
---
2022 (in thousands):

| ​                              
 ​                              | ​ 
 ​ | ​ 
 ​ | As of December 31, 
 2023               |   |      |   | ​ | ​ | 2022 |   |      |   | ​ 
 ​ |
|:-------------------------------|:--|:--|:-------------------|:--|-----:|:--|:--|:--|:-----|:--|-----:|:--|:--|
| Licensed patent rights         | ​ | ​ | ​                  | $ |  826 | ​ | ​ | ​ | ​    | $ |  826 | ​ | ​ |
| Less: accumulated amortization | ​ | ​ | ​                  | ​ | -378 | ​ | ​ | ​ | ​    | $ | -315 | ​ | ​ |
| Total intangible assets, net   | ​ | ​ | ​                  | $ |  448 | ​ | ​ | ​ | ​    | $ |  511 | ​ | ​ |

As of December 31, 2023, the expected remaining amortization expense is as follows (in thousands):

| Year Ended December 31, 
 2024                    | ​ 
 ​ | ​ 
 ​ | Amount 
 ​      |   |  63 | ​ | ​ 
 ​ |
|:------------------------|:--|:--|:-------|:--|----:|:--|:--|
| 2025                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2026                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2027                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2028                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| Thereafter              | ​ | ​ | ​      | ​ | 133 | ​ | ​ |
| Total                   | ​ | ​ | ​      | $ | 448 | ​ | ​ |

The Company recognized less than $0.1 million for amortization expense for each of the years ended December 31, 2023 and 2022, respectively. Amortization expense is included in research and development expense in the statements of operations and comprehensive loss. 6. Accrued Expenses Accrued expenses consisted of the following as of December 31,